论文部分内容阅读
目的探讨单唾液酸四已糖神经节苷脂钠注射液(GM1)治疗儿童格林-巴利综合征(GBS)的疗效。方法将符合GBS诊断标准的38例患儿随机分为两组,对照组18例,给予静脉滴注免疫球蛋白(IVIG)、地塞米松注射液;治疗组20例,在对照组治疗的基础上加用GM1,并对两组疗效进行对比观察。结果 GM1治疗组在控制病情进展和改善恢复方面明显优于对照组(P<0.05),且未见不良反应。结论 GM1治疗儿童GBS安全有效。
Objective To investigate the efficacy of GM1 in treatment of Guillain-Barre syndrome (GBS) in children. Methods Thirty-eight children who met GBS diagnostic criteria were randomly divided into two groups. The control group received intravenous immunoglobulin (IVIG) and dexamethasone injection. In the treatment group, 20 patients were treated by the control group Add GM1, and compare the efficacy of the two groups observed. Results The GM1 treatment group was significantly better than the control group (P <0.05) in the control of disease progression and improvement of recovery, and no adverse reactions were observed. Conclusion GM1 is safe and effective in treating children with GBS.